2008
DOI: 10.1016/j.jorganchem.2008.05.023
|View full text |Cite
|
Sign up to set email alerts
|

N-versus O-silylation in cis-[(tBuHN)OP(μ-NtBu)2PO(NHtBu)] and [Me2Si(μ-NtBu)2PO(NHPh)]. Solid-state structures of their silylation products, of co-crystalline cis-[(tBuHN)OP(μ-NtBu)2PO(NHtBu)], and of {[Me2Si(μ-NtBu)2PO(N(SiMe3)Ph)]VCl3}

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
6
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(7 citation statements)
references
References 36 publications
1
6
0
Order By: Relevance
“…[20][21][22] Recently,t hese species have experienced as low but steady renaissance,and the chemistry of cyclodiphosphazane compounds is regaining momentum within the main group arena. This is illustrated by their implementation in nontraditional areas where these species had little influence,such as catalysts for organic synthesis, [23][24][25] antitumor drugs, [26,27] and small molecule activation. [28,29] Thevast majority of structures comprising P III atoms and/ or their applications have been based on disubstituted cyclodiphosphazane monomeric species (Figure 1, type m III ).…”
Section: Introductionmentioning
confidence: 99%
“…[20][21][22] Recently,t hese species have experienced as low but steady renaissance,and the chemistry of cyclodiphosphazane compounds is regaining momentum within the main group arena. This is illustrated by their implementation in nontraditional areas where these species had little influence,such as catalysts for organic synthesis, [23][24][25] antitumor drugs, [26,27] and small molecule activation. [28,29] Thevast majority of structures comprising P III atoms and/ or their applications have been based on disubstituted cyclodiphosphazane monomeric species (Figure 1, type m III ).…”
Section: Introductionmentioning
confidence: 99%
“…1) are saturated four-membered P 2 N 2 heterocycles that can easily be synthesized with different substitution patterns on phosphorus and nitrogen from commercially available amines and PCl 3 . While achiral P III/V -cyclodiphospazanes have been studied as ligands in transition-metal chemistry [2223], only two examples of cyclodiphosphazanes as catalysts in asymmetric reactions are known; Chakravarty et al [24] tested an ansa -bridged BINOL-based P V -cyclodiphosphazane in the asymmetric reduction of acetophenone with BH 3 (5–8% ee), while Gade et al [25] recently introduced BINOL-based P III -cyclodiphosphazane ligands to transition-metal catalysis (up to 84% ee). We anticipated that by incorporation of a chiral amido-scaffold into bis(amido)cyclodiphosphazanes ( cis -[R'NHP(S)(μ-NR)] 2 ), bulky and conformationally constrained bidentate HB catalysts with an improved H-acidity should be accessible.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, these species have experienced a slow but steady renaissance, and the chemistry of cyclodiphosphazane compounds is regaining momentum within the main group arena. This is illustrated by their implementation in non‐traditional areas where these species had little influence, such as catalysts for organic synthesis, [23–25] antitumor drugs, [26, 27] and small molecule activation [28, 29] …”
Section: Introductionmentioning
confidence: 99%
“…[20][21][22] Recently,t hese species have experienced as low but steady renaissance,and the chemistry of cyclodiphosphazane compounds is regaining momentum within the main group arena. This is illustrated by their implementation in non-traditional areas where these species had little influence,such as catalysts for organic synthesis, [23][24][25] antitumor drugs, [26,27] and small molecule activation. [28,29] Thevast majority of structures comprising P III atoms and/ or their applications have been based on disubstituted cyclodiphosphazane monomeric species (Figure 1, type m III ).…”
Section: Introductionmentioning
confidence: 99%